Principal Investigator Alireza Faridar, M.D. to provide overview of data for the investigator-initiated "Phase II Clinical Trial of Interleukin-2 (IL-2) in Patients with Mild to Moderate Alzheimer's disease" Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the principal investigator of a low-dose IL-2 Phase 2 study in Alzheimer's disease (AD), Alireza Faridar, M.D. from Houston Methodist Hospital, will be presenting previously announced progress to date at the ADPD 2025 conference in Vienna. The presentation, titled, "A Phase II Clinical Trial o

Regulatory T cell-derived exosomes (Treg exosomes) have demonstrated strong and consistent therapeutic potential in suppressing inflammation in preclinical models of neurodegenerative diseases as previously published here Treg exosomes are end-stage differentiated, making them less likely to be affected by pro-inflammatory factors that may impact their suppressive function The work planned includes GMP processes and manufacturing activities and the production of larger-scale clinical batches in the fourth quarter of 2025, in preparation for a first in human study Funded by the Johnson Center for Cellular Therapeutics, Hop On A Cure, and Energy Transfer, with Coya holding exclusive rights

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and announces its financial results for the year ended December 31, 2024. Corporate Highlights FY2024 to Date Announced significant improvements of inflammatory blood markers from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of low-dose interleukin-2 (LD IL-2) in patients with Alzheimer's disease (AD) Announced that five of eight patients have been enrolled in the investigator-initiated academic study of LD IL-2 + CTLA4-Ig combinat

D. Boral Capital initiated coverage of Coya Therapeutics with a rating of Buy and set a new price target of $15.00

4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

4 - Coya Therapeutics, Inc. (0001835022) (Issuer)

10-K - Coya Therapeutics, Inc. (0001835022) (Filer)

8-K - Coya Therapeutics, Inc. (0001835022) (Filer)

SCHEDULE 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

Secretary Ross has over 55 years' experience as a business leader, banker, and investor and is the former Chairman and Chief Strategy Officer of WL Ross & Co. Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced that it has appointed Secretary Wilbur Ross to its board of directors, effective immediately. Coya intends to leverage Secretary Ross's extensive experience in both the business and investment community to help guide strategic partnering activities, capital markets initiatives and drug development programs. S

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, today released the following letter to stockholders from its Chief Executive Officer and Chairman, Dr. Howard Berman. Dear Fellow Stockholders, As the year comes to a close, I want to take a moment to reflect on Coya's accomplishments and share our strategic vision for the coming year. We set ambitious goals at the beginning of 2023 and I am pleased to say that our team rose to the occasion. Throughout the year, we notched several "wins," culminating in a transformative licensing transaction, announced December 6th, 2023, with Dr

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of regulatory T cells ("Tregs"), announced today that it has entered into definitive securities purchase agreements for the purchase and sale of an aggregate of 4,370,382 shares of its common stock at a purchase price of $6.06 per share of common stock, in a private placement priced at-the-market under Nasdaq rules. The offering is expected to close on or about December 11, 2023, subject to the satisfaction of customary closing conditions. The financing included participation by former U.S. Secretary of Commerce Wi

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results will be presented simultaneously via a poster on Tuesday, October 29, at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD24) in Madrid, Spain. The Phase 2 study was led by KOLs Dr. Alireza Faridar and Dr. Stanley

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the third quarter ended September 30, 2023, and provided a clinical and business update. Q3 2023 and Recent Highlights Completed enrollment in a randomized, double-blind, placebo-controlled Phase 2 study of Low Dose IL-2 in patients with mild-to-moderate Alzheimer's Disease (AD). The study is being conducted by Drs. Stanley Appel and Alireza Faridar at the Houston Methodist Hospital and is funded by the Gates Foundation and Alzheimer's As

Coya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics and cell therapies intended to enhance the function of Regulatory T Cells (Tregs), today announced its financial results for the second quarter ended June 30, 2023, and provided a clinical and business update. Q2 2023 and Recent Highlights Presented positive results from a proof-of-concept (PoC), open-label, investigator-initiated clinical study of low dose interleukin-2 (ld IL-2) + CTLA4 Ig in Amyotrophic Lateral Sclerosis (ALS) illustrating enhancement of Treg function during the treatment period, halting of disease progression at 24 weeks and minimal decline a

SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)

SC 13G/A - Coya Therapeutics, Inc. (0001835022) (Subject)